A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.

Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotroph...

Full description

Saved in:
Bibliographic Details
Main Authors: Dowsett, M., Mehta, A., Mansi, J., Smith, I. E.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 1990
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1971512/
https://ncbi.nlm.nih.gov/pubmed/2123115
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items